Search results for "BINDING PROTEIN"

showing 10 items of 1292 documents

Phenotype associated with TAF2 biallelic mutations: a clinical description of four individuals and review of the literature

2021

International audience; Transcription factor IID is a multimeric protein complex that is essential for the initiation of transcription by RNA polymerase II. One of its critical components, the TATA-binding protein-associated factor 2, is encoded by the gene TAF2. Pathogenic variants of this gene have been shown to be responsible for the Mental retardation, autosomal recessive 40 syndrome. This syndrome is characterized by severe intellectual disability, postnatal microcephaly, pyramidal signs and thin corpus callosum. Until now, only three families have been reported separately. Here we report four individuals, from two unrelated families, who present with severe intellectual disability and…

AdultMaleAdolescentFoot Deformities CongenitalDevelopmental DisabilitiesAutosomal recessiveIntellectual disabilityPostnatal microcephaly[SDV.GEN] Life Sciences [q-bio]/GeneticsBiologyCorpus Callosum03 medical and health sciencesNeurodevelopmental disorderNeurodevelopmental disorderIntellectual disabilityGeneticsmedicineHumansMissense mutationGlobal developmental delayTAF2ChildGeneAllelesGenetics (clinical)Exome sequencing030304 developmental biologyGeneticsTATA-Binding Protein Associated Factors0303 health sciences[SDV.GEN]Life Sciences [q-bio]/Genetics030305 genetics & heredityGeneral Medicinemedicine.diseasePhenotypeChild PreschoolTAF2MicrocephalyFemaleTranscription Factor TFIID
researchProduct

FUS mutations in sporadic amyotrophic lateral sclerosis

2011

Mutations in the FUS gene have recently been described as a cause of familial amyotrophic lateral sclerosis (ALS), but their role in the pathogenesis of sporadic ALS is unclear. We undertook mutational screening of all coding exons of FUS in 228 sporadic ALS cases, and, as previous reports suggest that exon 15 represents a mutational hotspot, we sequenced this exon in an additional 1295 sporadic cases. Six variants in six different cases were found, indicating that FUS mutations can underlie apparently sporadic ALS, but account for less than 1% of this form of disease. © 2010 .

AdultMaleAgingAmyotrophic lateral sclerosis; FUS; Italy; Sporadic disease; United States of America;AdolescentGenotypesporadic patientsDNA Mutational AnalysisALS; FUS mutations; sporadic patientsBiologymedicine.disease_causeArticlePathogenesisExonYoung AdultDNA Mutational AnalysisGenotypemedicineHumansFUS mutationsAmyotrophic lateral sclerosisChildGeneAgedGeneticsAged 80 and overMutationGeneral NeuroscienceAmyotrophic Lateral Sclerosisamyotrophic lateral sclerosis FUS geneticsExonsMiddle Agedmedicine.diseaseUnited StatesSettore MED/26 - NEUROLOGIAItalyMutationRNA-Binding Protein FUSFemaleNeurology (clinical)Geriatrics and GerontologyALSDevelopmental BiologyRNA-Binding Protein FUS
researchProduct

Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation

2009

Recently, fused in sarcoma/translated in liposarcoma (FUS/TLS) gene, located on chromosome 16p11.2, has been identified as a disease gene in familial amyotrophic lateral sclerosis (FALS). We have analyzed FUS/TLS in a cohort of 52 index cases from seven Italian regions with non-SOD1 and non-TARDBP FALS. We identified a heterozygous c.G1542C missense mutation in a family of northern Italian origin, and a heterozygous c.C1574T missense mutation in a family of Sicilian origin. Both variants are located in exon 15 encoding the RNA-recognition motif, and result in a substitution of an arginine with a serine in position 514 (p.R514S) and substitution of a proline with a leucine at position 525 (p…

AdultMaleAgingamyotrophic lateral sclerosisAdolescentDNA Mutational AnalysisMutation MissenseBiologyArticleCohort StudiesExonYoung AdultDegenerative diseasemedicineMissense mutationHumansFamilygeneticsAmyotrophic lateral sclerosisAge of OnsetGeneamyotrophic lateral sclerosis; geneticsAgedGeneticsGeneral NeuroscienceMiddle Agedmedicine.diseasePhenotypePedigreePhenotypeSLA - FUS mutation - geneticsItalyMutationDisease ProgressionRNA-Binding Protein FUSFemaleSettore MED/26 - NeurologiaNeurology (clinical)Geriatrics and GerontologyAge of onsetMissenseAmyotrophic lateral sclerosis; Family pedigrees; FUS gene; Genetics;Developmental BiologyRNA-Binding Protein FUS
researchProduct

Analysis of chronic lymphotic leukemia transcriptomic profile: differences between molecular subgroups

2009

B cell chronic lymphocytic leukemia (CLL) is a lymphoproliferative disorder with a variable clinical course. Patients with unmutated IgV(H) gene show a shorter progression-free and overall survival than patients with immunoglobulin heavy chain variable regions (IgV(H)) gene mutated. In addition, BCL6 mutations identify a subgroup of patients with high risk of progression. Gene expression was analysed in 36 early-stage patients using high-density microarrays. Around 150 genes differentially expressed were found according to IgV(H) mutations, whereas no difference was found according to BCL6 mutations. Functional profiling methods allowed us to distinguish KEGG and gene ontology terms showing…

AdultMaleCancer ResearchBCL6BiologyIgVHgenomichemic and lymphatic diseasesmedicineHumansKEGGGenemicroarraysAgedAged 80 and overRegulation of gene expressionGeneticsB-LymphocytesGene Expression ProfilingZAP70HematologyMiddle Agedmedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsGene Expression Regulation NeoplasticGene expression profilingLeukemiaOncologyTranscriptomicHealthMutationProto-Oncogene Proteins c-bcl-6Cancer researchImmunoglobulin heavy chainFemaleImmunoglobulin Heavy ChainsCLL
researchProduct

Expression of nm23 in gastric carcinoma: association with tumor progression and poor prognosis.

1998

BACKGROUND Expression of nm23 has been shown to be inversely correlated with the metastatic potential of several human cancers. In the current study, the expression and prognostic impact of nm23 was immunohistochemically studied in 413 curatively resected gastric carcinomas. METHODS Tumor sections of the 413 gastric carcinomas were stained with a polyclonal antibody that was raised against the nm23-H1/NDP kinase A, which is identical to the nm23-H1 gene product. RESULTS Expression of nm23 was detected in 84.5% (n = 349) of all tumors, in the majority of cases (71.2%) causing a homogeneous staining reaction in more than 75% of tumor cells. Expression of nm23 was positively correlated with th…

AdultMaleCancer ResearchMetastasisAntigens NeoplasmStomach NeoplasmsLymphatic vesselBiomarkers TumorMedicineHumansLymph nodeAgedMonomeric GTP-Binding ProteinsAged 80 and overbusiness.industryStomachCarcinomaCancerMiddle AgedNM23 Nucleoside Diphosphate Kinasesmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyTumor progressionNucleoside-Diphosphate KinaseCancer researchAdenocarcinomaImmunohistochemistryFemalebusinessCarcinoma Signet Ring CellTranscription FactorsCancer
researchProduct

Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors.

2010

More than 90% of all Ewing's Sarcoma Family of Tumors (ESFT) exhibit specific chromosomal rearrangements between the EWS gene on chromosome 22 and various members of the ETS gene family of transcription factors. The gene fusion type and other secondary genetic alterations, mainly involving cell cycle regulators, have been shown to be of prognostic relevance in ESFT. However, no conclusive results have been reported. We analyzed the clinicopathological significance of relevant cell cycle regulators in genetically confirmed ESFT. A total of 324 cases were analyzed for the immunohistochemical expression of p53, p21(Waf1/Cip1) , p27(Kip1) and Ki67 and the chromosomal alterations of the p53 and …

AdultMaleCancer ResearchPathologymedicine.medical_specialtyAdolescentChromosomes Human Pair 22Sarcoma EwingBiologyFusion geneCohort StudiesYoung AdultGene mappingmedicineBiomarkers TumorHumansProgression-free survivalChildIn Situ Hybridization FluorescenceAgedAged 80 and overCell CycleCancerEwing's sarcomaInfantCell cycleMiddle Agedmedicine.diseaseGenes p53ImmunohistochemistryOncologyChild PreschoolCancer researchFemaleSarcomaChromosome DeletionRNA-Binding Protein EWSChromosome 22International journal of cancer
researchProduct

Early stage human colorectal cancer: prognostic value of nm23-H1 protein overexpression

1997

Nm23 gene codifies for a nucleoside diphosphate kinase allowing the intracellular transduction of the signals. In colorectal cancer nm23 protein expression seems related to the progression of the disease. By immunohistochemistry we have studied the intracytoplasmatic nm23 H1 protein expression in 20 patients affected by colorectal cancer at initial stage. In 12 cases it resulted elevated and in four the disease recurred. The overexpression was not correlated with other prognostic factors. Nm23 H1-positive patients affected by colorectal cancer at initial stage could be considered at risk for disease recurrence and included in a more frequent follow-up protocol.

AdultMaleCancer ResearchPathologymedicine.medical_specialtyColorectal cancerRectumDiseaseMouse model of colorectal and intestinal cancerGene expressionBiomarkers TumormedicineCarcinomaHumansAgedMonomeric GTP-Binding ProteinsNeoplasm StagingAged 80 and overbusiness.industryMiddle AgedNM23 Nucleoside Diphosphate KinasesPrognosismedicine.diseaseNucleoside-diphosphate kinaseNeoplasm Proteinsmedicine.anatomical_structureOncologyNucleoside-Diphosphate KinaseDisease ProgressionCancer researchImmunohistochemistryFemaleColorectal NeoplasmsbusinessTranscription FactorsCancer Letters
researchProduct

Poorly differentiated synovial sarcoma: A case report

2001

Poorly differentiated synovial sarcoma is a rare soft tissue tumor. We studied a case arising in the pleural cavity of a young subject, characterised by the presence of spindle cell, small cell, and large epithelioid cell areas. We performed stains for mucosubstances and analysed the expression of cytokeratins 5/6, 7, 8, 18, 19, CEA, CD34, Ber-Ep4 and calretinin to characterize the phenotype of this neoplasm. We furthermore assessed immunohistochemically the presence of p53, Bcl-2, Bax and caspase 3, four apoptotic markers, to evaluate a relationship between apoptotic activity and the behaviour of this tumor. Our findings showed a strong presence of calretinin, p53 and Bcl-2 in all three ar…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyPleural Neoplasms2734CD34Caspase 3Pathology and Forensic MedicineSynovial sarcomaImmunoenzyme TechniquesSarcoma SynovialS100 Calcium Binding Protein GBcl-2-associated X proteinCalretininProto-Oncogene ProteinsBiomarkers TumormedicineHumansCaspasebcl-2-Associated X ProteinbiologyCaspase 3ApoptosiSoft tissue tumorGeneral MedicinePoorly differentiated synovial sarcomamedicine.diseaseSynovial sarcomaNeoplasm ProteinsApoptosis; Calretinin; Poorly differentiated synovial sarcoma; Soft tissue tumors; Synovial sarcoma; Cancer Research; Oncology; 2734Proto-Oncogene Proteins c-bcl-2OncologyCalbindin 2Caspasesbiology.proteinSarcomaTumor Suppressor Protein p53CalretininEpithelioid cell
researchProduct

BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia

2009

BCL6 somatic mutations affect normal and tumoral post germinal center B-lymphocytes. Our objective was to analyse expression, mutations and polymorphisms in the BCL6 gene and to correlate those variables with the clinical outcome in early-stage chronic lymphocytic leukemia (CLL). CLL samples were used for characterisation of the mutational status of BCL6/ immunoglobulin variable heavy chain (IGHV) genes, and expression of BCL6 was determined by real time PCR and immunoblot. Out of 68 cases, 29% show somatic mutations on BCL6 which occur exclusively in IGHV mutated cases. They are single nucleotide substitutions located mainly in two short mutational hot spots. CLL cells express different le…

AdultMaleCancer ResearchSomatic cellChronic lymphocytic leukemiaBiologyPredictive Value of Testsimmune system diseaseshemic and lymphatic diseasesmedicineHumansPoint MutationGeneAgedAged 80 and overPolymorphism GeneticGenes ImmunoglobulinGerminal centerHematologyMiddle AgedPrognosismedicine.diseaseBCL6Leukemia Lymphocytic Chronic B-CellDNA-Binding ProteinsTreatment OutcomeReal-time polymerase chain reactionOncologyMutationImmunologyProto-Oncogene Proteins c-bcl-6biology.proteinFemaleAntibodyImmunoglobulin Heavy ChainsIGHV@Leukemia & Lymphoma
researchProduct

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group.

2016

Clinical impact of GATA2 mutations in acute myeloid leukemia patients harboring CEBPA mutations: a study of the AML study group

AdultMaleCancer Researchmedicine.medical_specialtyMyeloidAdolescentmedicine.disease_causeCohort Studies03 medical and health sciencesYoung Adult0302 clinical medicinehemic and lymphatic diseasesInternal medicineCEBPAmedicineHumansneoplasmsAgedMutationHematologybusiness.industryMyeloid leukemiaHematologyMiddle Agedmedicine.diseaseLymphomaGATA2 Transcription FactorHaematopoiesisLeukemiaLeukemia Myeloid Acutemedicine.anatomical_structureOncology030220 oncology & carcinogenesisMutationCancer researchCCAAT-Enhancer-Binding ProteinsFemalebusiness030215 immunologyLeukemia
researchProduct